The Cyclophilin Inhibitor Rencofilstat Decreases HCV-Induced Hepatocellular Carcinoma Independently of Its Antiviral Activity

Mostrar otras versiones (1)

There is an urgent need for the identification of new drugs that inhibit HCV-induced hepatocellular carcinoma (HCC). Our work demonstrates that cyclophilin inhibitors (CypIs) represent such new drugs. We demonstrate that the nonimmunosuppressive cyclosporine A (CsA) analog (CsAa) rencofilstat posses...

Descripción completa

Detalles Bibliográficos
Autores principales: Stauffer, Winston, Bobardt, Michael, Ure, Daren, Foster, Robert, Gallay, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612079/
https://www.ncbi.nlm.nih.gov/pubmed/37896876
http://dx.doi.org/10.3390/v15102099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612079/
https://www.ncbi.nlm.nih.gov/pubmed/37896876
http://dx.doi.org/10.3390/v15102099

Ejemplares similares